Integration of Geriatric Measures Alongside Disease-Based Measures to Advance Precision Oncology for Older Veterans with Multiple Myeloma
Integration of Geriatric Measures Alongside Disease-Based Measures to Advance Precision Oncology for Older Veterans with Multiple Myeloma
批准号:
10426038
负责人:
Clark William DuMontier
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-10-01 至 2025-09-30
关键词:
AdoptedAgeAmerican Society of Clinical OncologyAttenuatedAwardChemotherapy-Oncologic ProcedureChronicChronic DiseaseClinicClinical InvestigatorCodeCollaborationsCommunicationCytogeneticsDataDatabasesDecision MakingDevelopmentDiagnosticDiseaseEffectivenessElderlyElectronic Health RecordFutureGeneticGenotypeGeriatric AssessmentGeriatricsGoalsHealthHealth systemHealthcareHospitalizationInformation CentersIntegrated Health Care SystemsInterdisciplinary StudyInvestigationK-Series Research Career ProgramsLeadershipMachine LearningMalignant NeoplasmsMassachusettsMeasuresMentorsMentorshipMissionModelingMultiple MyelomaNew EnglandOlder PopulationOncologistOncologyOutcomePatternPerformance StatusPhenotypePhysiologicalPrognosisRegimenResearchResearch PersonnelResearch TrainingResourcesRiskSeveritiesStatistical Data InterpretationSurvival RateTestingTimeToxic effectTrainingTraining ProgramsTranslatingTreatment ProtocolsTriplet Multiple BirthVeteransWorkage relatedbasebig-data sciencebody systemchemotherapyclinical centerclinical decision supportcohortcomparative effectivenessdata warehouseeducation researchelectronic dataepidemiology studyexperiencefrailtyhospitalization rateshuman old age (65+)indexinginnovationmortalitymultiple chronic conditionsolder patientoncology programpersonalized cancer therapypersonalized carepersonalized medicineprecision oncologypredictive modelingprognosticrisk stratificationroutine caresafety studyskillssociodemographic variablesstressorsupport toolssurvival predictiontooltumor
中文摘要
虽然领先的癌症组织,如美国临床医学会,
肿瘤学现在建议对所有患有癌症的老年人进行老年评估,
由于以下方面的限制,评估尚未在VA和其他地方广泛采用
资源、老年医学专业知识和在忙碌的肿瘤诊所的时间。国家精密
肿瘤学项目正在分析骨髓瘤和其他癌症的肿瘤遗传学,
疾病和个性化治疗以前所未有的方式。然而,真正个性化的癌症
老年退伍军人的治疗不仅必须基于肿瘤的“基因型”,而且还必须基于老年人
“显型”Clark DuMontier博士是一位老年病学家和临床研究者,专注于整合
将老年医学纳入肿瘤学。为CDA-2提出的研究将促进博士。
DuMontier的长期目标是开发可行有效的工具,帮助VA肿瘤学家整合
脆弱性和多发性骨髓瘤以及骨髓瘤特异性因素,以推进精确的肿瘤学,
患有骨髓瘤的老兵本申请的目的是电子测量
在VA新治疗的5000多名年龄≥ 65岁的骨髓瘤退伍军人中的虚弱和多发性骨髓瘤
从2004年至今,使用VA全国综合医疗保健数据,
卫生系统。初步研究结果表明,虚弱和多发性硬化可以迅速
使用诊断和程序代码以及电子健康记录中的数据进行评估
(EHR)。目标1将确定电子脆弱指数VA-FI是否能独立预测
患有骨髓瘤的老年退伍军人的死亡率和住院率,以及它是否改变了
对这些结果的影响。分析将包括重要的骨髓瘤特异性因素
如三联或双联化疗、分期和细胞遗传学、社会人口学变量
和预后实验室目标2将确定多模态模式是否独立预测
骨髓瘤的死亡率和住院率,以及它们是否改变了特定方案的效果
这些结果。机器学习分析将应用于67种慢性疾病
在VA数据库中进行测量,以定义这些模式及其对老年退伍军人的影响,
骨髓瘤目标3将开发和验证死亡率的预测风险模型,
虚弱和多发性骨髓瘤特异性因子。一旦验证,该模型将
翻译成嵌入在VA EHR中的临床决策支持工具。该工具将帮助
肿瘤学家快速评估虚弱和多发性硬化,并提高个体化预后
和治疗决策的老年退伍军人骨髓瘤。受指导的研究和培训
该CDA-2中描述的计划将加速DuMontier博士发展成为一个独立的
退伍军人事务部老年肿瘤学研究员。他的导师团队包括Jane Driver博士、Nikhil
Munshi、Michael Gaziano和玛丽布罗菲--老年医学、肿瘤学和大数据科学领域的领导者
来自新英格兰老年医学研究教育临床中心(GRECC),
马萨诸塞州退伍军人流行病学研究和信息中心(MAVERIC),以及
VA国家精确肿瘤学计划。在这些导师的指导下,
与MAVERIC合作,DuMontier博士将继续接受培训,提供(1)经验
具有大型数据库调查;(2)高级统计分析和机器方面的专业知识
学习;(3)项目管理和多学科合作;(4)沟通,
领导技能和专业发展。这项培训和指导研究将为
他是竞争的VA优秀奖走向独立作为VA临床研究者。
英文摘要
Although leading cancer-focused organizations such as the American Society of Clinical
Oncology now recommend geriatric assessments for all older adults with cancer, these
assessments have not been widely adopted within VA and elsewhere due to limitations in
resources, geriatrics expertise, and time in busy oncology clinics. The VA National Precision
Oncology Program is profiling tumor genetics in myeloma and other cancers to characterize
disease and personalize therapy in unprecedented fashion. However, truly personalized cancer
treatment for older Veterans must be based not only on tumor “genotype,” but also on older adult
“phenotype.” Dr. Clark DuMontier is a geriatrician and clinical investigator focused on integrating
geriatric measures into oncology. The research proposed for this CDA-2 will advance Dr.
DuMontier’s long-term goal of developing feasible and valid tools to help VA oncologists integrate
frailty and multimorbidity alongside myeloma-specific factors to advance precision oncology for
older Veterans with myeloma. The objectives of this application are to electronically measure
frailty and multimorbidity in over 5000 Veterans age ³ 65 years with myeloma newly treated in VA
from 2004-present using healthcare data that is readily available within VA’s nationally integrated
health system. Preliminary findings demonstrate that frailty and multimorbidity can be rapidly
assessed using diagnostic and procedural codes and data from the electronic health record
(EHR). Aim 1 will determine whether an electronic frailty index, the VA-FI, independently predicts
mortality and hospitalizations in older Veterans with myeloma, and whether it modifies the effect
of initial therapy on these outcomes. Analyses will include important myeloma-specific factors
such as triplet or doublet chemotherapy, stage and cytogenetics, sociodemographic variables,
and prognostic labs. Aim 2 will determine whether multimorbidity patterns independently predict
mortality and hospitalizations in myeloma, and whether they modify the effect of specific regimens
on these outcomes. A machine learning analysis will be applied to 67 chronic conditions
measured within the VA database to define these patterns and their impact in older Veterans with
myeloma. Aim 3 will develop and validate a predictive risk model for mortality that incorporates
frailty and multimorbidity with myeloma-specific factors. Once validated, this model will be
translated into a clinical decision support tool embedded in the VA EHR. This tool will help VA
oncologists to rapidly estimate frailty and multimorbidity and enhance individualized prognosis
and treatment decisions for older Veterans with myeloma. The mentored research and training
program described in this CDA-2 will accelerate Dr. DuMontier’s development into an independent
VA investigator in geriatric oncology. His mentorship team includes Drs. Jane Driver, Nikhil
Munshi, Michael Gaziano, and Mary Brophy—leaders in geriatrics, oncology, and big data science
from the New England Geriatric Research Education Clinical Center (GRECC), the
Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), and the
VA National Precision Oncology Program. Under the guidance of these mentors and in
collaboration with MAVERIC, Dr. DuMontier will pursue training that will provide (1) experience
with large database investigation; (2) expertise in advanced statistical analyses and machine
learning; (3) project management and multidisciplinary collaboration; and (4) communication,
leadership skills, and professional development. This training and mentored research will prepare
him to be competitive for a VA Merit Award toward independence as a VA clinician investigator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integration of Geriatric Measures Alongside Disease-Based Measures to Advance Precision Oncology for Older Veterans with Multiple Myeloma
-
批准号:10578715
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Clark William DuMontier
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: